Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)

National Institutes of Health · United States government procurement

GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

November 15, 2027
Response Due
Active
Status

Opportunity Overview

Through this Notice of Funding Opportunity (NOFO), entitled "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI), the National Cancer Institute (NCI) encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. TTNCI awards are designed to mature experimental nanomedicines relying on nanoparticles and nano-devices which demonstrate strong potential to improve cancer treatment effectiveness due to the combination of nanoparticle/nano-device structural design and/or therapeutic/diagnostic cargo which is delivered. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

This is one of 1,273 active United States Health Services opportunities most of your competitors will never see.

Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyNational Institutes of Health
CountryUnited States
CategoryHealth Services
NAICS93.395
PublishedDecember 16, 2024
Procurement stageRequest for Proposal (RFP)
Response dueNovember 15, 2027
StatusOpen — accepting responses
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: U.S. Government (Grants.gov) — public domain. Not affiliated with or endorsed by the United States Government.

Related Opportunities in United States

Development of Collaborative Research Facilities or Research-Resource Facilities (C06 Clinical Trial Not Allowed)
NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)
NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Not Allowed)
NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed)
Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
NIH Director’s New Innovator Award (DP2 Clinical Trial Optional)
Limited Competition: Superfund Hazardous Substance Research and Training Program (P42 Clinical Trial Optional)
Limited Competition: Intellectual and Developmental Disabilities Research Centers 2027 (P50 Clinical Trial Optional)

See every United States Health Services opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United States Health Services intelligence report in your inbox

A personalized report on United States Health Services opportunities, emailed in 5-10 minutes. One per month, no account needed.